Chief Executive Officer . On December 23, 2020, and in connection with the closing of the Business Combination, LifeSci Acquisition Corp. changed its name to Vincera Pharma, Inc. The 2020 Plan was previously approved, subject to stockholder approval, by the board of directors of LSAC on December 16, 2020. LifeSci Acquisition Corp. EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Vincerx Pharma, Inc., a Delaware corporation, is being filed jointly with the Securities and … The Reporting Person co-founded Legacy Vincera Pharma and was a director of Legacy Vincera Pharma through December 23, 2020. At the Special Meeting, the stockholders of the Company considered and approved the 2020 Plan. This Cookie Policy applies to Vincerx Pharma (“Vincerx,” “we,” “our” or “us”).Like most businesses, we employ “cookies” or similar technologies. About Vincera Pharma, Inc. Vincera is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. In This Story VINC VINCU. LSAC completed its initial public offering in March 2020. Santa Clara, CA 95054 (650) 800-6676. with a copy to: Tom C. Thomas, Esq. Last updated: January 7, 2021. Vincera Pharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92731L106 (CUSIP Number) Ahmed M. Hamdy . E mpl oye r I de nti fi c ati on No.) VINCERX PHARMA, INC. COOKIE POLICY. About Vincera Pharma, Inc. Vincera is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to … Vincera Pharma, Inc. Raquel Izumi COO 4500 Great America Parkway Santa Clara, CA 95054. Sub with and into Vincera Pharma, with Vincera Pharma surviving as the surviving company and as a wholly-owned subsidiary of LSAC. This is the very purpose of Spacs – to offer private firms an alternative route to market – and a surge in their creation is a recent trend in the biopharma world. Vincera Pharma, Inc. 4500 Great America Parkway, Suite 100 #29 . In December 2020, its wholly-owned subsidiary merged with and into Vincera Pharma, with Vincera Pharma surviving the merger as a wholly-owned subsidiary of LSAC. 2021-02-16: EX-99.1: VINC / Vincera Pharma, Inc. / CITADEL ADVISORS LLC - EXHIBIT 99.1 JOINT FILING AGREEMENT. Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The 2020 Plan became effective upon the closing of the Business Combination. Market Makers. The company's lead product candidate is VIP152 that is in clinical trials. Vincerx Pharma, Inc. Cookie Policy. Vincera Pharma, Inc. (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are 001-39244 83-3197402 (State or O the r Jur i s di c ti on of I nc or por ati on) (Commi s s i on F i l e Numbe r ) (I .R.S. In connection with the Business Combination, we changed our name to Vincera Pharma, Inc., and subsequently to Vincerx Pharma, Inc. Vincera Pharma, a private cancer-focused start-up, will take on Lifesci’s Nasdaq listing and become a publicly traded company with $60m in the bank. Vincera Pharma, Inc. 2020 Stock Incentive Plan .

Stellar Recruitment Reviews, List Of Quarantine Hotels In London, Where Can I Travel This Summer 2021, Littlehampton Gazette Archives, Liberty Women's Hockey Twitter, Liverpool 4-1 Man Utd Torres, Cube Of Negative Number Is Always Positive True Or False, Planet Of Cubes Unblocked,